- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03790917
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY (ANTEY)
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY Profile. Prospective Observational Study. ANTEY Study
A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.
Primary Study Objective(s) Primary study objective The aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with CV disease complicated by non-valvular atrial fibrillation requiring OAC treatment within the outpatient registry PROFILE (prospective, observational study).
- Data collection in patients with non-valvular atrial fibrillation requiring OAC treatment included in the registry
- Evaluation of actual patient adherence to OACs
Secondary Study Objective(s)
- Evaluation of potential patient adherence to OACs
- Determination of the most significant factors associated with adherence to OACs in patients with non-valvular AF
- Validation of new original 5-item Questionnaire
- Evaluation of doctor's adherence to OAC prescription according to Guidelines (ESC). Management of atrial fibrillation,2016)
연구 개요
상태
정황
상세 설명
AF patients from ongoing PROFILE registry will be invited to visit the scientific center.
2 visits with a 6-month interval are expected for each patient as part of routine clinical practice and phone contact is scheduled for each patient 1 year from the first visit to the scientific center (follow-up period).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Moscow, 러시아 연방, 101990
- National Research Center for Preventive Medicine
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Men and women above 18 years of age who were included in the PROFILE registry by the start of the observational study
- Presence of written informed consent to participate in the study, fill in the study questionnaires and have personal data analyzed
- Presence of any form of non-valvular atrial fibrillation with CHA2DS2-VASc score of ≥1 or patients with CHA2DS2-VASc score = 0, who are already taking OAK
Exclusion Criteria:
Patients with high bleeding risk, including patients with:
- Congenital or acquired bleeding disorders
- Uncontrolled resistant hypertension
- Exacerbation of gastric and duodenal ulcer
- Vascular retinopathy
- Recent history of intracranial or intracerebral hemorrhage
- Pathology of the brain and spinal cord vessels
- Recent history of brain, spinal cord or eye surgery
- History of bronchiectasis or pulmonary hemorrhage
- A CHA2DS2-VASc score of 0 (OACs are not indicated)
- Pregnancy, lactation
- Planned surgery
- Known hypersensitivity to ingredients of medications used in the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Proportions of Adherent, Partially Adherent, Partially Non-adherent and Completely Non-adherent Patients (NSEPh During V1)
기간: 6 months
|
The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs. Adherence to therapy was assessed during V1 with the use of the original questionnaire - National society of evidence-based pharmacotherapy (NSEPh) adherence scale. |
6 months
|
Proportions of Adherent, Partially Adherent, Partially Non-adherent and Completely Non-adherent Patients (NSEPh During Phone Contact)
기간: 1 year
|
The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0. During V0 all patients were recommended to start therapy with one of the NOACs. Adherence to therapy was assessed during phone contact with the use of the original questionnaire - National society of evidence-based pharmacotherapy (NSEPh) adherence scale. Out of 201 participants of the study 4 patients died and 197 patients completed the study. |
1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Proportion of Potentially Adherent Patients
기간: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
Specifically designed 5-item questionnaire was used for assessment of potential adherence to OACs.
According to results patients were divided into groups: completely adherent, partially adherent, completely non-adherent to OACs.
|
Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
Proportion of OACs Prescribed by Doctors According to Guidelines
기간: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
Prescription of OACs according to guidelines was considered "positive" if it matched the key points of 2016 ESC Guidelines for the management of atrial fibrillation.
|
Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
The Main Reasons for Refusing to Start NOAC Therapy
기간: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0.
During V0 all patients were recommended to start therapy with one of the NOACs.
Patients refusing to start NOAC treatmet were asked about the reasons to refuse NOAC treatment.
|
Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
Reasons for Stopping Oral Anticoagulants (Data From Visit 1)
기간: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC))
|
The study consisted of two visits half a year apart (V0, V1) and phone contact (PC) one year after V0.
During V0 all patients were recommended to start therapy with one of the NOACs.
Patients who stopped or didn't start NOAC treatment were asked about the reasons for non-adherence to anticoagulants use during visit 1 (6 months) and at PC (1 year).
|
Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC))
|
Reasons for Stopping Oral Anticoagulants (Data From the Phone Contact)
기간: Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
The study consisted of two visits half a year apart (V0, V1) and a phone contact (PC) one year after V0.
During V0 all patients were recommended to start therapy with one of the NOACs.
Patients who stopped NOAC treatmet were asked about the reasons for stopping oral anticoagulants (NOAC and warfarin) use during the phone contact.
|
Total - 1 year (two timepoints - 6 months (V1) and 1 year (PC)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sergey Martsevich, MD,PhD, National Research Center of Preventive Medicine
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심방세동에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음과도한 Supraventricular Ectopies 또는 Short Atrial Runs(ESVEA)
-
University of Pennsylvania빼는전형적인 심방 조동 | Atrial Flutter의 향후 개발 위험 요소미국